Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Aug
09
Today In Oncology
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer
WHO Calls for Action in New Status Report on Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo